Proteostasis Therapeutics

Proteostasis Therapeutics files IND for PTI-808, cystic fibrosis potentiator

Monday, July 3, 2017

Proteostasis Therapeutics, a biopharmaceutical company developing small molecule therapeutics to treat diseases caused by dysfunctional protein processing such as cystic fibrosis (CF), announced that the company has filed an Investigational New Drug (IND) application with the FDA for PTI-808, its cystic fibrosis transmembrane conductance regulator (CFTR) potentiator. Proteostasis plans to initiate a phase I study of PTI-808 in healthy volunteers in July.

[Read More]

Proteostasis Therapeutics, Astellas form $1.2B collaboration

Wednesday, November 5, 2014

Proteostasis Therapeutics, a Cambridge, Mass.-based company developing novel therapeutics to address diseases caused by defects in protein folding, trafficking and clearance, and Astellas Pharma have entered into a worldwide R&D collaboration for therapeutic candidates that modulate the unfolded protein response (UPR) through the use of Proteostasis Therapeutics’ proprietary Disease Relevant Translation (DRT) and Proteostasis Network platform.

[Read More]

Proteostasis, Scripps Research expand collaboration on cystic fibrosis

Friday, July 27, 2012

Proteostasis Therapeutics, a therapeutics developer focusing on regulating protein homeostasis for neurodegenerative and orphan diseases, has expanded its collaboration with The Scripps Research Institute (TSRI) to encompass an additional funded research project focused on biology and the testing of small molecule modulators of protein folding and trafficking for the treatment of cystic fibrosis (CF).

[Read More]